Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids.
Willis
A L
AL
Atherosclerosis and Thrombosis Section, Syntex Research, Palo Alto, CA 94304.
Smith
D L
DL
Vigo
C
C
D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism / Q000517:prevention & control*; D001792:Blood Platelets / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism; D008934:Mitogens / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011453:Prostaglandins / Q000627:therapeutic use*
D008934:Mitogens; D011453:Prostaglandins; D002784:Cholesterol; D011464:Epoprostenol